Saranac Partners’s Amgen AMGN Stock Holding History

Saranac Partners’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-136	Closed	-$37.3K	–	83
2025 Q3	$37.3K	Buy	+136	New	+$39.4K	0.01%	295

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Saranac Partners's AMGN Position: Q4 2025 in Review

Saranac Partners sold out of Amgen (AMGN) in Q4 2025, closing a stake of 136 shares — an estimated $37.3K sold.

Saranac Partners first reported a position in AMGN in Q3 2025 and held it in 1 quarter. The position peaked at $37.3K in Q3 2025. 3,088 funds tracked by Wall St. Rank hold AMGN as of Q4 2025.

Saranac Partners reported no remaining Amgen position as of Q4 2025 after selling out during the quarter.
Saranac Partners sold 136 Amgen shares in Q4 2025, an estimated $37.3K.
Saranac Partners first reported a position in Amgen in Q3 2025 and held it in 1 quarter.
Saranac Partners's Amgen position peaked at $37.3K in Q3 2025.
3,088 funds tracked by Wall St. Rank held Amgen as of Q4 2025.

Based on Saranac Partners's 13F filing for Q4 2025, filed 6 Feb 2026.